Par Pharmaceutical Companies Inc. (PRX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

300 TICE BOULEVARD WOODCLIFF LAKE, NJ 07677

Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.

View SEC Filings from PRX instead.

View recent insider trading info

Funds Holding PRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LEPORE PATRICK G EXECUTIVE CHAIRMAN

  • Officer
  • Director
No longer subject to file 2012-09-28 0

ZENNER PATRICK J

  • Director
0 2012-09-28 0

SHAROKY MELVIN MD

  • Director
No longer subject to file 2012-09-28 0

NORDMANN RONALD M

  • Director
No longer subject to file 2012-09-28 0

KNIGHT PETER S

  • Director
No longer subject to file 2012-09-28 0

SMITH JOSEPH E

  • Director
No longer subject to file 2012-09-28 0

RICE THOMAS P

  • Director
No longer subject to file 2012-09-28 0

HAUGHEY THOMAS PRESIDENT

  • Officer
  • Director
No longer subject to file 2012-09-28 0

CAMPANELLI PAUL CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2012-09-28 0

TROPIANO MICHAEL A EVP AND CHIEF FINANCIAL OFFICE

  • Officer
No longer subject to file 2012-09-28 0

MACPHEE JOHN A EVP, PRES-STRATIVA

  • Officer
105,903 2011-01-11 0

KENYON LAWRENCE A

  • FORMER EVP AND CFO
No longer subject to file 2010-08-02 0

ABERNATHY JOHN D

  • Director
0 2010-01-04 0

FLYNN JAMES E

DEERFIELD MANAGEMENT CO /NY

DEERFIELD INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2009-08-17 0

SEIDMAN L WILLIAM

  • Director
0 2009-01-08 0

LUBATKIN VERONICA EVP, CHIEF FINANCIAL OFFICER

  • Officer
50,606 2008-12-31 0

MARTINO GERARD

  • FORMER EVP AND COO
109,054 2008-12-22 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD MANAGEMENT CO /NY

DEERFIELD INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
11,149,448 2008-11-25 0

FLYNN JAMES E

DEERFIELD CAPITAL LP

DEERFIELD PARTNERS, LP

DEERFIELD MANAGEMENT CO /NY

DEERFIELD INTERNATIONAL LTD

  • 10% Owner
  • POSSIBLE MEMBERS OF 10% GROUP
3,877,916 2008-11-06 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments